Vanda Pharmaceuticals | VNDA - 销售和管理费用



金融业
股票价格
USD
资产
USD 488.95M
现金及等价物
USD 84.85M
销售成本
USD 198.77M
流动资产
USD 347.26M
流动负债
USD 145.16M
债务
USD 4.96M
股息收益率
0
EBIT
USD -10.28M
EBITDA
USD -8.31M
员工
203
EPS每股收益
USD -0.09
股本和储备
USD 327.19M
销售毛利
USD 50.6M
债务利息支出
-1.37B
贷款资金
USD 3.15M
市值
USD 357.3M
净收入
USD -18.9M
营业费用
USD -1.14B
营业利润
USD -40.66M
普通股股本
USD 58K
PE价格收益
16.79
税前利润
USD -22.92M
销售收入
USD 198.77M
销售和管理费用
USD 39.28M
股票
USD 1.85M
贸易债权人
USD 39.09M
应收帐款人
USD 47.1M


销售和管理费用 更改 日
Acadia Pharmaceuticals USD 160.79M 14.06M 2026-03
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Akebia Therapeutics USD 23.53M 3.19M 2025-12
Alnylam Pharmaceuticals USD 282.51M 2.55M 2026-03
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 41.74M 4.28M 2026-03
AstraZeneca USD 5.06B 455M 2026-03
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Eli Lilly USD 2.93B 198M 2026-03
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Esperion Therapeutics USD 39.42M 456K 2025-12
Halozyme Therapeutics USD 46.29M 18.35M 2026-03
Heron Therapeutics USD 23.74M 605K 2025-12
Insmed USD 247.26M 34.78M 2026-03
J&J USD 6.03B 719M 2026-03
Lexicon Pharmaceuticals USD 3.98M 195K 2025-12
Ligand Pharmaceuticals USD 20.84M 4.19M 2026-03
Merck USD 2.67B 180M 2026-03
Minerva Neurosciences USD 2.48M 58.79K 2024-09
Moderna USD 173M 135M 2026-03
Novartis USD 3.44B 132M 2025-12
Pfizer USD 2.92B 1.16B 2026-03
PTC Therapeutics USD 73.89M 13.31M 2026-03
Puma Biotechnology USD 16.82M 8.15M 2024-09
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.33B 419M 2026-03
Takeda JPY 292B 9.21B 2026-03
Teva Pharmaceutical Industries USD 1000M 120M 2026-03
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12
Veracyte USD 50.84M 7.53M 2026-03